The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy by Savino, Mauro et al.
The Action Mechanism of the Myc Inhibitor Termed
Omomyc May Give Clues on How to Target Myc for
Cancer Therapy
Mauro Savino
1, Daniela Annibali
1, Nicoletta Carucci
1, Emilia Favuzzi
1, Michael D. Cole
2¤a, Gerard I.
Evan
3¤b, Laura Soucek
3,4, Sergio Nasi
1*
1Consiglio Nazionale delle Ricerche - Istituto di Biologia e Patologia Molecolari (CNR – IBPM), Dipartimento di Biologia e Biotecnologie, Universita ` Sapienza, Roma, Italia,
2Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America, 3Department of Pathology, University of California San
Francisco (UCSF), San Francisco, California, United States of America, 4Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Abstract
Recent evidence points to Myc – a multifaceted bHLHZip transcription factor deregulated in the majority of human cancers
– as a priority target for therapy. How to target Myc is less clear, given its involvement in a variety of key functions in healthy
cells. Here we report on the action mechanism of the Myc interfering molecule termed Omomyc, which demonstrated
astounding therapeutic efficacy in transgenic mouse cancer models in vivo. Omomyc action is different from the one that
can be obtained by gene knockout or RNA interference, approaches designed to block all functions of a gene product. This
molecule – instead – appears to cause an edge-specific perturbation that destroys some protein interactions of the Myc
node and keeps others intact, with the result of reshaping the Myc transcriptome. Omomyc selectively targets Myc protein
interactions: it binds c- and N-Myc, Max and Miz-1, but does not bind Mad or select HLH proteins. Specifically, it prevents
Myc binding to promoter E-boxes and transactivation of target genes while retaining Miz-1 dependent binding to
promoters and transrepression. This is accompanied by broad epigenetic changes such as decreased acetylation and
increased methylation at H3 lysine 9. In the presence of Omomyc, the Myc interactome is channeled to repression and its
activity appears to switch from a pro-oncogenic to a tumor suppressive one. Given the extraordinary therapeutic impact of
Omomyc in animal models, these data suggest that successfully targeting Myc for cancer therapy might require a similar
twofold action, in order to prevent Myc/Max binding to E-boxes and, at the same time, keep repressing genes that would be
repressed by Myc.
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Introduction
Myc transcriptional regulators – c-, N- and L-Myc – are
basic, helix-loop-helix, leucine zipper (bHLHZip) proteins that
bind to an array of genomic sites to either induce or repress
transcription of genes important for cell growth, metabolism
and differentiation [1–4]. These factors – especially c-Myc and
N-Myc – are deregulated in the majority of human cancers.
This is usually not due to Myc gene mutation but results from
upstream mutations affecting other oncogenes or tumor
suppressors. Myc activity thus appears to be required for
development and maintenance of the majority of tumors, even
when initiated by other causes. In tumors induced by Myc
upregulation in transgenic mice, even brief Myc de-activation
triggers tumor regression accompanied by growth arrest,
differentiation, and collapse of the tumor vascular system [5].
Myc operates within a highly interconnected interactome
network and a possible strategy for targeting Myc oncogenic
function is dominant interference of Myc protein interactions.
In this respect, Myc oligomerization domain – the bHLHZip
region – proved to be capable of dominantly inhibiting Myc
transforming ability in rat embryo fibroblast cells [6,7]. This
domain mediates the direct interaction with Max and sequence
specific binding to specific consensus sequences – the E boxes –
in promoters of activated target genes. The bHLHZip domain
is also involved in the interaction with other partners – such as
Miz-1 – that mediate transcriptional repression by Myc [4,8].
To interfere with Myc protein-protein interactions, we
developed a dominant negative molecule by introducing four
selected mutations in the bHLHZip region of human c-Myc.
The resulting 90 amino acid miniprotein – termed Omomyc
for its capacity to form homodimers – is able to inhibit c-Myc/
Max association, to affect transcriptional activation by c-Myc,
and to enhance c-Myc dependent apoptosis in tissue culture
cells [9,10]. It was shown to prevent c-Myc induced
papillomatosis in vivo without affecting tissue homeostasis [11]
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damaging the normal tissue.
Despite its pervasive role in human cancer, Myc met with
considerable skepticism as a therapeutic target since its requirement
for proliferation and maintenance of adult stem cell compartments
raised concern about the toxicity of Myc inhibition for healthy
tissues [12,13]. In part thanks to work on Omomyc the potential of
Myc as a therapeutic target is now established. Many doubts about
selectivity for tumors have been dispelled by studies showing that
transiently inhibiting Myc in skin, intestinal epithelium and other
tissues does not dramatically alter tissue homeostasis [11,14,15].
The efficacy and safety of Myc targeting a ` la Omomyc has been
conclusively demonstrated by reversible expression of Omomyc in
transgenic models [16,17]. Systemic expression of Omomyc
attenuated proliferation in rapidly dividing tissues, but this was
well-tolerated; tissue homeostasis was maintained, no apoptosis was
observed in the normal tissues and all side effects were readily
reversed following Omomyc removal. In Ras-driven lung tumors,
the impact of Omomyc was impressive. Mice continuously
expressing Omomyc failed to develop lung adenocarcinoma. In
mice that had previously developed advanced cancer, induction of
Omomyc triggered tumor regression which was accompanied by
reduced proliferation and increased apoptosis of the tumor tissue
[16]. An analogous anticancer impact was found in a simian virus
40(SV40)-drivenpancreaticislettumormodel[17],inbreastcancer
(G.Evan,personal communication)andglioma (inpreparation).So,
manipulating Myc function similarly to Omomyc might have the
potential of an effective anticancer strategy for various tumor types.
In view of the striking properties of this molecule, it is extremely
relevant to elucidate its mechanism of action. Omomyc biological
effects are simply the results of tout court Myc function ablation, as it
would occur with Myc gene or mRNA knockouts? Clearly, to
explain the remarkable properties of Omomyc it is important to
understand whether they result from selective targeting of the Myc
interactome and how they impact on the Myc activated and
repressed targets. These issues are addressed in the present work.
Our data indicate that Omomyc does not cause a global
inhibition of Myc function but acts as an edge-specific perturbation
of the Myc interactome, channeling its activity towards transrepres-
sion. This may be key to its success as an anticancer agent.
Results
Omomyc selectively targets the Myc interactome
Direct physical interaction with the bHLHZip protein Max is
crucial to Myc function: the Myc/Max complex binds DNA –
recognizing E-boxes – and works as a transcriptional activator [18].
Omomyc is able to homodimerize, to form heterodimers with c-
Myc and Max proteins, and to interfere with c-Myc/Max complex
formation and binding to E-boxes in vitro [9,10]. To better address
Omomyc selectivity we investigated its capacity to bind N-Myc –
which shares substantial functional redundancy with c-Myc and has
important roles in tumor formation in the nervous system –, Mad –
a strictly related bHLHZip factor that dimerizes with Max, binds E-
boxes and acts as transcriptional repressor [4] –, Heb and Id1 – two
HLH proteins representative of a large family of transcriptional
regulators implicated in developmental processes [19]. To assess the
capacity to bind N-Myc we performed immunoprecipitations on
293T cells ectopically expressing Omomyc fused to the oestrogen
receptor ER
TM – Omomer [10] – together with FLAG tagged c- or
N-Myc. We found that Omomyc bound to N-Myc similarly to c-
Myc (Figure 1A), in agreement with the virtual identity of the
bHLHZip domain amino acid sequences of Myc family proteins.
To assess binding to Max, Mad and the two HLH proteins Heb (an
E protein) and Id1 we performed pull-down assays with GST-linked
Max, Mad, Heb and Id1 on extracts of 293T cells ectopically
expressing FLAG-tagged Omomyc. Whereas binding to Max was
strong as previously reported [9], Omomyc binding to Mad was
barely visible and binding to Heb and Id1 was undetectable
(Figure 1B).Thefaintsignal intheGST-Madpull-downislikelydue
to the very high levels of FLAG-Omomyc expression in the
transfected cells and not reflective of physiological interaction
between the two proteins. In summary, we found that Omomyc
binding specificity for Max and Mad proteins was the same as Myc.
Similarly to Myc, Omomyc does not appear to interact with HLH
proteins and therefore does not act by disrupting HLH protein
networks crucial for differentiation control [20–22]. We then asked
wether Omomyc interacted with Hypoxia-inducible factor 1-alpha
(Hif-1a), a protein that functions as a master transcriptional
regulator of the adaptive response to hypoxia, plays an essential
role in tumor angiogenesis and shows a considerable interplay with
Myc in the regulation of multiple glycolytic genes [23–25]. Hif-1a
contains a bHLH domain and antagonizes Myc by binding to Max
[24]. To investigate Omomyc binding to Hif-1a we performed
immunoprecipitations on 293T cells ectopically expressing FLAG
tagged Omomyc together with Hif-1a. We found (Fig. 1C) that
Omomyc does not bind Hif-1a, while Max does as reported.
Altogether,theseexperimentsclearlyindicatethat OmomycisMyc-
Max-Mad network specific and – within this network – selectively
affects Myc/Max dimerization, required for Myc binding to E-
boxes and transactivation of a large number of genes.
A key aspect of Myc function is transrepression of numerous
genes involved in growth control, differentiation and tumor
suppression [4]. This activity does not appear to implicate direct
Myc binding to E-boxes. Myc is recruited to promoters of
repressed genes only indirectly, upon interaction with proteins that
directly bind to such promoters. The best known of them is Miz-1,
a zinc finger protein involved in Myc dependent repression of cell
cycle inhibitors – p15-INK4b (Cyclin-dependent kinase 4 inhibitor
B) and p21(CDKN1: cyclin-dependent kinase inhibitor 1) – and in
Myc dependent apoptosis in response to growth factor withdrawal
[26–29]. Presumably in complex with Max, Myc contacts Miz-1
N-terminal region through the amino acid sites D394 and S405
[28] that are located in the HLH region. As these sites are not
mutated in Omomyc, we hypothesized that Omomyc retained the
capability to bind Miz-1. We tested this possibility via immuno-
precipitation on 293T cells ectopically expressing Omomer and
Miz-1. Figure 1D demonstrates that Omomyc directly interacts
with Miz-1. Endogenous Miz-1 was reported to accumulate in the
cytoplasm of cells, with a minor fraction in the nucleus; Myc
overexpression triggers nuclear translocation of Miz-1 and
sequestration in discrete subnuclear foci [30]. To investigate the
interaction and intracellular localization of Omomyc, Omomyc/
Miz-1 and Omomyc/c-Myc complexes, we transfected 293T cells
with FLAG tagged Omomyc or c-Myc expressing plasmids
together with plasmids expressing untagged Miz-1 and c-Myc,
and detected protein localization by immunofluorescence with anti
FLAG, c-Myc, and Miz-1 antibodies (Figure 2). In cells transfected
with single expression plasmids, Miz-1 was mostly (about 90%)
localized in the cytoplasm as previously reported [30], Myc was
present exclusively in the nucleus as expected, and Omomyc was
largely in the nucleus (about 85%) with a minor part in the
cytoplasm (Figure 2). Omomyc lacks the nuclear localization signal
of Myc proteins: it may enter the nucleus due to its small size or
upon dimerization with endogenous Myc or Max. When co-
transfected, most Myc proteins co-localized with Omomyc in the
nucleus; a fraction of Omomyc remained in the cytoplasm - not
associated to Myc - likely due to a higher level of expression.
The Action Mechanism of Omomyc
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(about 40%) and formation of discrete subnuclear foci, as
previously reported [30]. Miz-1 was partly relocated in the
nucleus in the presence of an overexpressed Omomyc as well
(about 35%). Endogenous Miz-1 – which is present in low
amounts within cells [30] – will presumably be mostly in the
nucleus in the presence of an overexpressed Myc or Omomyc.
Altogether, these findings show that perturbation of the Myc
interactome by Omomyc results not only from the inhibition of
Myc binding to Max – which is required for E-box binding and
transactivation – but also from the interaction of Omomyc with
Miz-1, a Myc binding partner involved in transrepression.
Omomyc affects the transcriptional response of
fibroblasts to serum stimulation
Myc proteins are able to bind to 10–20% of genomic loci and to
modulate expression of hundreds to thousands of genes. Omomyc
was shown to impair transactivation of the Myc activated target
gene cad in Rat1 fibroblasts and not to affect downregulation of the
Myc repressed target gadd45 [10]. To get an insight into
widespread gene expression changes influenced by Omomyc, we
analyzed the transcriptional response to serum stimulation of Rat1
fibroblasts stably infected with an Omomer producing or an empty
retrovirus (Rat1-Omomer and Rat1-control cells, respectively, as
described in [10]). c-Myc is known to be downregulated by serum
starvation and sharply induced by serum addition – together with
a number of other immediate early genes – reaching a peak after 1
to 2 h; c-Myc induction has a role in cell cycle re-entry [31–33].
Apart from cell proliferation, the serum response of fibroblasts
integrates other processes – e. g. wound healing [34] – and serum
regulated genes include genes that are regulated by Myc as well as
genes that are not. Cells were serum-starved before serum
stimulation and mRNA expression was analyzed at the time of
serum re-addition (time 0) and 909 thereafter – a time point at
which Myc induction is maximal – so that induction of a direct
Myc target should closely follow the expression of Myc. mRNA
Figure 1. Omomyc binding specificity. A) Omomyc binds c-Myc and N-Myc. Immunoblotting (WB) with FLAG and ER antibodies – as
indicated – of immunoprecipitations performed with FLAG antibodies on 293T cells transfected with FLAG-c-Myc or FLAG-N-Myc expressing vectors
together with the Omomer expressing vector. B) Omomyc binds Max but not Mad and two representative HLH proteins. Immunoblotting
(WB) with FLAG antibodies of GST pull-down assays performed with GST, GST-MAX, GST-MAD, GST-ID1 and GST-HEB (10 ı `g each) on 293T cells
transfected with the FLAG-Omomyc expressing vector. 293T cells transfected with ID2 or FLAG-13I [65] expressing vectors were used as positive
control for GST-HEB and GST-ID1, respectively. Extracts from bacteria expressing His-MAX were used as positive controls for GST-MAX and GST-MAD.
C) Omomyc does not bind Hif-1a. Immunoblotting (WB) with Hif-1a, Max and FLAG antibodies – as indicated – of immunoprecipitations
performed with FLAG antibodies on 293T cells transfected with Hif-1a, Max and FLAG-Omomyc expressing vectors. D) Omomyc binds Miz-1.
Immunoblotting (WB) with Miz-1 and ER antibodies – as indicated – of immunoprecipitations performed with Miz-1 antibodies on 293T cells
cotransfected with Miz-1 and Omomer expressing vectors.
doi:10.1371/journal.pone.0022284.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22284Figure 2. Omomyc intracellular co-localization with Miz-1 and c-Myc. A) Immunofluorescence photomicrographs of 293T cells transfected
with Miz-1, c-Myc, FLAG-c-Myc and FLAG-Omomyc expressing plasmids - as indicated above panels - and stained with antibodies against FLAG
(green), Miz-1 (red) and c-Myc (red) as indicated inside panels. Nuclei of the same fields were stained in blue with DAPI (4,6-diamidino-2-
phenylindole). B) Quantitation of the experiments shown in A), based on the examination of 15 microscopy field and at least three biological
replicates.
doi:10.1371/journal.pone.0022284.g002
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probes for approximately 7,000 full-length sequences and 1,000
EST (expressed sequence tags) clusters. Data are accessible in the
GEO database with the following accession number: GSE25039.
Relative mRNA expression values (Fold Changes) were computed
by taking as reference Rat1-control cells at time 0; only genes
showing a Fold Change of at least +3 (upregulated genes) or 23
(downregulated genes) were taken into account. At the time of
serum stimulation, Omomer expressing and control Rat1 cells
displayed a virtually identical gene expression profile (Figure 3,
top). At 90 min of serum induction 111 sequences were
upregulated and 96 downregulated in Rat1-control cells. Strik-
ingly, a pronounced downregulation was found in Rat1-Omomer
cells: as many of 516 gene sequences were downregulated and 143
upregulated (Table S1). Overall, the total number of sequences
whose expression was up or downregulated in the presence of
Omomyc after 90 min of serum stimulation amounted to 8.2% of
the probes on the array. Among the sequences downregulated in
the presence of Omomyc, 475 represented genes with a known
GeneID (gene identifier) and 41 other transcribed regions. To find
out whether genes downregulated in the presence of Omomyc
were also validated Myc targets we compared them to the set of
genes listed in the Myc Cancer Gene database (www.myccancer-
gene.org), a collection of Myc responsive genes identified in
Figure 3. Omomyc impact on the transcriptional response of Rat1 fibroblasts to serum stimulation. Omomyc promotes downregulation
of numerous genes. Top. Many more genes were downregulated in Rat1 cells expressing Omomer (Omomer) than in cells that do not (Control) at 909
following serum stimulation of Rat1 fibroblasts in the presence of tamoxifen. The number of upregulated genes was similar. Rat1-control cells at time
0 were taken as reference. Middle. Distribution in different Biological Process classes – based on Gene Ontology classification – of genes
downregulated at 909 following serum stimulation in Omomer and control cells. Bottom. Genes related to nucleotide and nucleic acid metabolism are
the most significantly over-represented – as computed by the Panther software – among the genes downregulated in the presence of Omomyc
(Omomer cells in the presence of tamoxifen).
doi:10.1371/journal.pone.0022284.g003
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(24%) of the 475 genes downregulated in the presence of Omomyc
were listed in the Myc target gene database: 45 were listed as
upregulated and 35 as downregulated by Myc, while the up or
down regulation of the remaining 35 genes was unknown. To
point out direct Myc targets within the list of genes downregulated
in the presence of Omomyc, the list was crossed with those from
two studies that used ChIP analysis to define genome wide
promoter occupancy by Myc in embryonic stem (ES) cells [36,37].
31.5% of the genes downregulated in the presence of Omomyc
had promoters that were reported to be directly bound by Myc in
ES cells (P-value: 1.3610
224) as compared to 19% in its absence
(P-value: 3610
22). Altogether, 44.4% of the Omomyc downreg-
ulated genes turned out to be genuine Myc targets according to
either the Myc target genes database or the listing of Myc bound
promoters in ES cells (Venn diagram: Figure 4A). Genes common
to all three groups are clustered in one dimension in Figure 4B.
Such a large – albeit incomplete – overlap among genes whose
downregulation was associated to Omomer activation in Rat1
fibroblasts and validated Myc targets is highly significant. That the
overlap is incomplete is consistent with other analyses of
expression and computationally derived gene sets [38,39], and it
might be due in part to other effects of serum. Figure 3 (middle)
shows the classification in functional categories based on GO
(Gene Ontology) terms. As reported for genes associated with c-
Myc activity [36,40,41], genes affected by Omomyc fall into
multiple functional classes involving growth, metabolism, cell
signaling pathways, cell cycle progression, and apoptosis. Notably,
genes downregulated in the presence of Omomyc were enriched in
categories – nucleotide and nucleic acid metabolism – that are
overrepresented among targets upregulated by c-Myc [36,40–42],
supporting the notion of Omomyc as an inhibitor of Myc
mediated transactivation (Figure 3, bottom). Targets known to
be upregulated by Myc and found to be downregulated by
Omomyc include genes encoding proteins directly involved in
translation and ribosome assembly – such as the translation
initiation factor Eif3s9, the translation elongation factor Eef1a1,
and the ribosomal protein L3 and S4 – as well as genes encoding
metabolic enzymes – isocitrate dehydrogenase 2, lactate dehydro-
genase B and phosphoglycerate kinase 1 –, proteins involved in cell
cycle progression – the anaphase-promoting complex subunit
Anapc5, Cyclin B1 and Cyclin D1 –, the ATPase/DNA helicase
TIP49 (Ruvbl1), and the structural chromatin protein Hmgb1.
Hmgb1 has an important role in chromatin remodeling and is a
mediator of inflammation whose overexpression is associated with
many tumor types [43]. TIP49 is an important Myc cofactor,
involved in Myc transcriptional and oncogenic functions [44].
Several genes found to be downregulated by Omomyc and known
to be Myc repressed targets encode proteins involved in signaling
pathways, cell adhesion and transcription – such as Akt1, Erbb2,
c-Jun and the fibroblast growth factor receptor Fgfr1 – while Mxi1
encodes a protein that interacts with Max and negatively regulates
Myc function. Mxi1 is repressed by Myc [45] but activated by Hif-
1a [46,47]. Defects in this gene have been reported in prostate
cancer and in a subset of glioblastomas [48,49].
To further validate our findings, we performed Real Time PCR
assays in wild type and Myc null Rat1 fibroblasts expressing
tamoxifen inducible Omomyc (Figure 4C). We compared – at 0
and 90 min of serum stimulation – the expression levels of a select
sample of genes affected by serum stimulation that are known to
be either repressed – Gadd45a, Mxi1, Erbb2, Akt1 – or activated –
Pgk1, Eif3s9, Ccnd1 – by Myc [40,45,50]. These genes, like any
gene, are not exclusive Myc targets, and other transcription factors
modulated or not by serum may contribute to their regulation. We
found that the expression levels of the repressed targets Gadd45a,
Mxi1, Erbb2 and Akt1 in wild type Rat1 cells were unaffected or
even more repressed in the presence of Omomyc whereas
upregulation of the activated targets Pgk1, Eif3s9 and Ccnd1 was
compromised (Figure 4C, left). In the Myc null cells, we found that
Omomyc did not significantly affect expression of the repressed
and did not impair upregulation of the activated targets (Figure 4C,
right). Therefore the effect of Omomyc on transcription of Myc
activated targets appears to require some activity of Myc.
In sum, these findings indicate that Omomyc does not globally
inhibit Myc function in transcriptional regulation of target genes
and suggest that it selectively perturbs the Myc transcriptome by
hampering Myc mediated transactivation and preserving Myc
mediated repression.
Omomyc differentially affects transactivation and
repression by influencing Myc binding to target gene
promoters
To investigate the mechanisms involved in gene regulation by
Omomyc, we performed luciferase reporter and chromatin
immunoprecipitation (ChIP) assays on two genes encoding the
nucleolar protein nucleolin and the cyclin-dependent kinase
inhibitor p21, respectively representing genuine and direct targets
of Myc mediated activation and repression [51,52]. c-Myc is able
to activate nucleolin transcription via two highly conserved E-boxes
in intron 1 [51]. To test the capability of Omomyc to inhibit Myc
mediated transcriptional activation, we performed reporter assays
in 293T cells transfected with the luciferase reporter plasmid
pNucL14 [51] – containing the mouse nucleolin promoter, exon 1,
intron 1 and the first 8 nt of exon 2 – together with different
combinations of FLAG-c-Myc and Omomyc expression plasmids
(Figure 5A). We found that Omomyc inhibited Myc mediated
activation of the luciferase reporter in a dose dependent manner,
while it did not affect its basal activity. To test whether the
inhibition of nucleolin transactivation by Omomyc was due to a
reduction of promoter binding, we measured the amount of Myc
bound to the nucleolin promoter on 293T cells transfected with
nucleolin reporter, FLAG-c-Myc and Omomyc expressing plasmids.
Recovery of nucleolin DNA coprecipitated with Myc was quantified
by real-time PCR, using primers located around the two E-boxes
in nucleolin intron 1. We found that Omomyc caused a 40%
reduction of the amount of promoter bound Myc (Figure 5B, left).
Besides competing for Myc/Max association, Omomyc is able to
form homodimers as well as Omomyc/Max dimers: only the latter
bind E-boxes in vitro with high efficiency [9]. Therefore, Omomyc
might affect Myc binding to DNA via two concurring mecha-
nisms: inhibition of Myc/Max dimerization as well as direct
competition for E-box binding. To assess the latter one, we
measured the amount of Omomyc bound to the nucleolin promoter
in cells transfected with c-Myc and FLAG-Omomyc expressing
plasmids (Figure 5B, right). We found that Omomyc was
specifically recruited to the E-box containing region in intron 1
and that it competed with c-Myc for binding to this region.
Altogether, these data indicate that Omomyc can affect transacti-
vation by sequestering Myc in complexes incapable of binding to
E-boxes as well as by acting – presumably in association with Max
– as competitive inhibitor of Myc/Max complexes for E-Box
binding.
To investigate how Omomyc may act to support Myc mediated
repression, we conducted assays on the human p21 promoter –
specifically the sequence comprised between 2194 and +16 from
the transcriptional start site – on which Myc is recruited by the
zinc finger protein Miz-1 [27,52]. We performed reporter assays
and found that luciferase expression driven by the full-length
The Action Mechanism of Omomyc
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Myc and that Omomyc was synergic with c-Myc (Figure 6A).
Interestingly – even in the absence of a cotransfected c-Myc –
Omomyc provoked p21 promoter repression to levels similar to the
ones caused by c-Myc. Therefore Omomyc is able to support p21
promoter repression both in the presence and absence of an over-
expressed c-Myc. To investigate whether this was associated to
increased promoter binding, we performed ChIP assays on 293T
cells transfected with the p21 reporter together with FLAG-Myc
and increasing amount of Omomyc plasmid. We observed that
Omomyc markedly increased c-Myc binding to the 2194 to +16
region (Figure 6B, top). Interestingly, the reciprocal assay on cells
Figure 4. Upregulation of Myc activated targets is compromised whereas downregulation of Myc repressed targets is supported by
Omomyc. A) Venn diagram illustrating the overlap among genes downregulated by Omomyc in the present study, genes listed as Myc targets in the
Myc target gene database (www.myccancergene.org), and genes reported to be directly bound by c-Myc in ES cells [29,38]. Within the Myc target
gene database and the ES cell datasets, only genes that had a probe on the Affymetrix U34A array were taken into account. B) Overlapping, bona fide
Myc target genes were extracted from our dataset and clustered in one dimension. C) Relative expression level (Fold Change) – measured by Real
Time PCR at 90 min following serum stimulation in the presence or absence of 4-OHT – of Ccnd1, Eif3s9, Pgk1, Akt1, Erbb2, Gadd45a, Mxi1 mRNAs in
wild type (left) and Myc null (right) Rat1 cells expressing tamoxifen inducible Omomyc (Omomer). Ccnd1, Eif3s9, Pgk1 represent Myc activated targets;
Akt1, Erbb2, Gadd45a, Mxi1 represent Myc repressed targets. Expression at the time of serum addition (time 0) was taken as reference for calculating
the Fold Change.
doi:10.1371/journal.pone.0022284.g004
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plasmid indicated that Omomyc was capable of interacting with
the same p21 promoter region (Figure 6B, bottom). In this case,
Myc overexpression did not compete with Omomyc binding.
These data support the hypothesis that transrepression of Myc
targets is sustained by Omomyc.
Epigenetic modifications associated to Myc activity are
affected by Omomyc
Myc proteins are involved in the widespread maintenance of
active chromatin. Disruption or downregulation of Myc expression
leads to decreased H3 and H4 acetylation at selected histone
residues accompanied by increased chromatin repressive marks,
an effect that is reversed upon Myc reactivation [3,38,54,55]. If
Omomyc indeed targets Myc function, its overexpression should
entail changes in the histone modifications associated with Myc
activity. To test this hypothesis, we performed immunohistochem-
istry assays to detect global levels of histone H3 lysine 9 acetylation
and dimethylation – representing marks of active and repressive
chromatin – reported to be respectively decreased and increased
upon Myc loss of function in neuronal progenitors and other cell
types [54,56]. N-Myc genomic binding is strongly linked to
H3AcK9 while loss of N-Myc decreases the pool of this active
chromatin mark [54]; 90% to 95% of the H3AcK9 mark in a
human neuroblastoma cell line was reported to be N-Myc
dependent [55]. We assessed levels of H3acK9 and H3diMeK9
in parental Rat1 cells (w. t.), in Rat1 cells harboring an inducible
Omomyc (Omomer) and in Rat1 cells harboring the inducible
Omomyc and an overexpressed c-Myc (Myc+Omomer) (Figure 7).
For a comparison, H3K9 acetylation and dimethylation was also
measured in Myc null Rat1 cells (Myc 2/2) and Myc null cells
harboring the tamoxifen inducible Omomyc (Myc 2/2 Omomer)
(Figure 8). We found that wild type Rat1 cells displayed significant
staining of H3acK9 and faint staining of H3diMeK9. Treatment
with tamoxifen triggered Omomer translocation to the nucleus, as
expected (Figures 7, top panels), which was accompanied by a
dramatic reduction of the H3acK9 signal, not affected by a
concomitant Myc overexpression (Figure 7, middle panels).
Omomyc caused an approximately four-fold reduction in
H3acK9 according to the densitometric analysis (Figure 7). Myc
null Rat1 cells displayed the opposite pattern to parental cells with
significant H3diMeK9 staining and a quasi-complete loss of
H3acK9 staining, similarly to what was reported for N-Myc null
neuroprogenitor cells [54]. This pattern was unaffected upon
Omomer induction (Figure 8). Of note, H3acK9 levels in
Omomyc overexpressing cells were even lower than observed in
Myc null cells, possibly due to compensatory events that occurred
in the latter. The H3K9 hypoacetylation observed upon Omomer
induction in the Omomer and Myc+Omomer expressing Rat1
cells was associated with a two-fold enhancement in dimethylation
of the same histone residue (Figure 7, bottom panels). In Myc null
fibroblasts, instead, Omomer induction did not affect the levels of
H3K9 dimethylation (Figure 8, bottom panels). The data
demonstrate that Omomyc impacts histone H3K9 acetylation
and methylation in an opposite way to Myc, leading to decreased
active and increased repressive chromatin marks.
Omomyc affects proliferation and survival of cells in
culture
Omomyc was shown to strongly potentiate Myc induced
apoptosis in murine myoblasts [10], and to slow growth and
trigger death of the tumor cells while sparing the surrounding
normal tissue in a lung adenocarcinoma model [16]. To further
assess its effects on cell growth and death, we determined
Figure 5. Omomyc inhibits Myc binding and transactivation of the nucleolin promoter. A) Luciferase activity of the mouse nucleolin
promoter reporter plasmid – pNucL14 – transfected in 293T cells together with FLAG-c-Myc and Omomyc expressing vectors. Data were normalized
by cotransfection of pRL-TK Renilla luciferase. The basal activity of the reporter was set to a value of 100. B) Quantitative ChIP assay of Myc and
Omomyc binding to the nucleolin promoter region (Ncl; grey bars). Left: FLAG-c-Myc binding in 293T cells transfected with the nucleolin reporter
pNucL14 together with FLAG-c-Myc and Omomyc expressing plasmids. Right: FLAG-Omomyc binding in 293T cells transfected with the nucleolin
reporter together with FLAG-Omomyc and c-Myc expressing plasmids. A region of the luciferase coding sequence (Luc; black bars) was used as
control. Bars represent the percentage of input DNA immunoprecipitated, after background subtraction. ChIP values are expressed as % of input
DNA.
doi:10.1371/journal.pone.0022284.g005
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expressing – or not – c-Myc and Omomer [10] (Figure 9A). In
the absence of tamoxifen, Rat1 cells expressing or not c-Myc and
Omomer had similar growth and death rate. Rat1-control and
Rat1-Omomer cells behaved similarly also upon tamoxifen
treatment, which modestly slowed down proliferation of both.
Rat1 cells co-expressing c-Myc and Omomer instead behaved
differently from the other two cell types in the presence of
tamoxifen: initially they grew similarly, but after two days their
proliferation stopped two due to massive cell death (Figure 9A).
Therefore, Omomyc appeared to only affect survival of Rat1 cells
over-expressing c-Myc, in agreement with the hypothesis that
activation of the cell death pathway requires Myc over-expression
[57]. Finally, we measured proliferation and death of SH-SY5Y
human neuroblastoma cells infected with Omomer producing or
control lentiviruses (Figure 9B). Switching on Omomyc activity by
tamoxifen in the neuroblastoma cells quickly inhibited growth and
triggered death, whereas tamoxifen had no effect on cells infected
with the control virus (Figure 9B). Omomer expression in
lentivirus infected neuroblastoma cells was stronger than in
Rat1-Omomer cells (not shown), suggesting that the greater
sensitivity of the neuroblastoma cell line – as compared to Rat1
cells – to the action of Omomyc might reflect its higher expression
level.
Discussion
The interest in Omomyc derives from its outstanding anti-
tumor activity, unparalleled by other Myc inhibitory treatments
[16]. This molecule selectively affects the Myc protein interaction
network. On the basis of our results, we propose that Omomyc
acts like an edge-specific perturbation of the network that produces
opposite effects on the two arms of Myc activity: transactivation
and transrepression of gene transcription. Edgetic perturbations of
a protein network confer distinct functional consequences from
node removal [58], achieved by technologies like gene knockout or
RNAi. The finding that Omomyc can bind N-Myc as well as c-
Myc and, presumably, all Myc family proteins suggests that it may
be able to prevent cells from eluding inhibition of a single Myc
protein by upregulating another Myc family member. Omomyc –
by inhibiting Myc interaction with Max – suppresses binding to E-
boxes and transactivation by Myc, whereas – by allowing Myc
interaction with Miz-1 – it favors binding to promoters of
repressed targets like p21 and transrepression. As a result, the Myc
network action is channeled to transrepression. This conclusion is
supported by the changes – in transcriptional response to serum
stimulation and epigenetic marks – observed in fibroblast cells
ectopically expressing Omomyc. Upon serum stimulation, many
more genes were downregulated in the presence of Omomyc than
Figure 6. Omomyc promotes Myc binding and transrepression
of the p21 (CDKN1) promoter. A) Luciferase activity of the human
p21 promoter reporter plasmid – p21Cip1-Luc – transfected in 293T
cells together with FLAG-c-Myc and Omomyc expressing plasmids. Data
were normalized by cotransfection of pRL-TK Renilla luciferase. The
basal activity of the reporter construct was set to a value of 100. B)
Quantitative ChIP assay of Myc and Omomyc binding to the p21
promoter region (p21cip1, grey bars). Top: FLAG-c-Myc binding in 293T
cells transfected with the p21 reporter p21Cip1-Luc together with
FLAG-c-Myc and Omomyc expressing plasmids. Bottom: FLAG-Omomyc
binding in 293T cells transfected with the p21 reporter together with
FLAG-Omomyc and c-Myc expressing plasmids. A region of the
luciferase coding sequence (Luc; black bars) was used as control. Bars
represent the percentage of input DNA immunoprecipitated, after
background subtraction. ChIP values are expressed as % of input DNA.
doi:10.1371/journal.pone.0022284.g006
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22284Figure 7. Omomyc influences – in an opposite way to c-Myc – the pattern of histone H3 lysine 9 acetylation and methylation,
leading to decreased active and increased repressive chromatin marks. Immunofluorescence staining (in green) of ER (top), H3acK9
(middle) and H3diMeK9 (bottom panels) in parental (w.t.), Omomer, and c-Myc + Omomer expressing Rat1 fibroblasts [12] grown for 48 h with or
without 4-OHT. DAPI staining (blue) was used for visualizing cell nuclei. The graphs below the immunofluorescence pictures display the quantitative
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Myc targets. Our data also suggest that Omomyc by itself may
directly contribute to downregulation of Myc repressed targets by
associating with Miz-1. It is presently unclear whether the
enhancement of transrepression by Omomyc may be solely
explained via Miz-1, as other transcription factors as well – e.g.
NFY and SP1 – have been reported to interact with Myc to
promote promoter binding and transrepression [4]. Further
experiments – like the design of Omomyc variants that hamper
the interaction with Miz-1 – will be required to assess these points.
Another contribution to the pro-repressive action is given by the
decrease of activating and the increase of repressive chromatin
marks – respectively H3K9 and H3diMeK9 – in the presence of
Omomyc. Myc elicits changes in the histone acetylation and
methylation patterns by two distinct mechanisms [54], both of
which can be affected by Omomyc. Specifically, Myc was shown
to recruit a number of proteins with chromatin modification
activity – histone acetyltransferases and methyltransferases, a H3-
specific kinase, a histone deacetylase, a histone H3-K4 dimethylase
[38,59] – and to activate target genes encoding chromatin
modification enzymes like the histone acetyltransferase GCN5
[54] and the Lysine-specific demethylase 5C [38]. While the
upregulation of these target genes by Myc is presumably
hampered by Omomyc, the direct influence of Omomyc on the
Figure 8. Omomyc does not influence the pattern of histone H3 lysine 9 acetylation and methylation in Myc null cells.
Immunofluorescence staining (in green) of ER (top), H3acK9 (middle) and H3diMeK9 (bottom panels) in parental (w.t.), c-Myc null (Myc 2/2), and c-
Myc null expressing Omomer (Myc 2/2 Omomer) Rat1 fibroblasts [12] grown for 48 h with or without 4-OHT. DAPI staining (blue) was used for
visualizing cell nuclei. The graphs at the right side of the immunofluorescence pictures display the quantitative analysis of H3AcK9 and H3diMeK9
staining: values represent fold change in histone H3 acetylation and dimethylation, relative to parental wild-type fibroblasts. Data were collected by
densitometric analysis of nuclear fluorescence from three independent biological repeats.
doi:10.1371/journal.pone.0022284.g008
analysis of H3AcK9 and H3diMeK9 staining. Values in the graphs represent fold change in histone H3 acetylation and dimethylation, relative to
parental wild-type fibroblasts. Data were collected by densitometric analysis of nuclear fluorescence from three independent biological repeats.
doi:10.1371/journal.pone.0022284.g007
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remains to be determined. Omomyc strongly affected proliferation
and apoptosis in two cell lines – immortalized Rat fibroblasts and a
human neuroblastoma – in a way that was correlated to its
expression level.
Clearly, Omomyc itself is not a therapeutic agent, but serves as
a tool that models the efficacy of future strategies that interfere
with Myc function in tumorigenesis [60]. Our study has
implications for the design of inhibitors that would target Myc
for cancer therapy. The development of small-molecule inhibitors
of protein-protein interactions is challenging, but significant
progress is being made and bHLH-ZIP proteins are considered
promising targets [13]. Most attempts to target Myc for cancer
therapy focused on inhibiting the Myc/Max association and
preventing Myc binding to E-boxes [12,13,61,62]. While this is
clearly a crucial issue, our data indicate that this is likely not to be
enough and that the repressing arm of Myc should be taken into
account. It may be equally important to safeguard at least some
aspects of the Myc transrepressive arm while disabling the
activating one. This conclusion is in agreement with evidence
indicating that transrepression has an important role in apoptosis,
senescence and tumorigenesis. The particular type of perturbation
introduced by Omomyc in the Myc interactome may turn the
transrepressive arm in a powerful tumor suppressor, promoting
cancer cell death.
Materials and Methods
Cell culture
Rat1 fibroblasts expressing Omomer and c-Myc + Omomer,
and c-Myc null Rat1 (myc 2/2) fibroblasts expressing Omomer
were described previously [10]. Rat1 (myc 2/2) fibroblasts were
obtained by J. Sedivy [63]. Rat1 and HEK 293T cells [64] were
cultured in complete DMEM medium and SH-SY5Y neuroblas-
toma cells [65] in DMEM F12, supplemented with 10% foetal calf
serum (EuroClone) and 1% penicillin/streptomycin at 37uCi n5 %
CO2. For Omomer induction, cells were treated with 4-OHT
(Sigma), added to the culture medium at a final concentration of
5610
27 M. For serum induction, cells were grown for 48 h in
0.1% serum (serum-starvation) and switched to media with 10%
serum in the absence or presence of 4-OHT (added 4 h before
switching to 10% serum). Transfections were performed using
Lipofectamine 2000 (Invitrogen).
Plasmids
Omomyc and Omomer expressing plasmids (pCS-Omomyc
and pBP-Omomer) were described previously [9,10]. c-Myc,
FLAG-c-Myc and FLAG-N-Myc expressing vectors (cbS-c-Myc,
cbSFLAG-c-Myc and cbSFLAG-N-Myc) were from M. Cole; the
Miz-1 expressing vector (pCMV-Miz-1) was from M. Eilers and
the Hif-1a vector (pCMV- Hif-1a) was obtainded from A. Levi.
GST-HEB and GST-ID1 expressing plasmids were previously
described [65]; the GST-MAD plasmid was from R. Eisenman
and the His-Max expressing plasmid was from L. Lania.
Luciferase reporters of the nucleolin and p21 promoters (pNucL14
and p21Cip1-Luc) were from B. Amati. The cbSFLAG-Omomyc
expression plasmid and the Tween lentiviral vector [66] expressing
FLAG-Omomer were assembled according to standard proce-
dures by means of the following oligonucleotide primers:
cbSFLAG-Omomyc: 59-GGCCCCCGGGACCGAGGAGAA-
TGTCAAGAGG-39 (forward) and 59-GGCCAAGCTTTTACG-
CACAAGAGTTCCGTAG-39 (reverse).
Tween-FLAG-Omomer 59-GGCCGTCGACATGGACTAC-
AAGGACGATGAT-39 (forward) and 59-GGCCGATATCAC-
TAGTAGGAGCTCTCAGAT-39 (reverse).
Pull-down assay
Pull-down assays with GST-linked proteins (Heb, Id1, Max,
MAD) were performed as previously described [65].
Coimmunoprecipitation
pBP-Omomer, pCMV-Miz-1, cbSFLAG-c-Myc, cbSFLAG-N-
Myc, pJ4V-Max, pCMV- Hif-1a and cbSFLAG-Omomyc
plasmids were transfected into 293T cells. After 2 days, cells were
collected and processed as previously described [65].
Immunoblotting
Western blot analysis was performed as described previously
[65], using the following antibodies and reagents: ER (MC20,
Santa Cruz Biotechnology; 1:1000 dilution), Miz-1 (H190, Santa
Cruz Biotechnology; 1:1000), Hif-1a (clone-54, BD Transduction
Laboratories; 1:1000), Max (c-124, Santa Cruz Biotechnology;
1:1000 dilution), and FLAG (M2, Sigma; 1:2500) antibodies;
peroxidase conjugated rabbit anti-mouse IgG (Chemicon;
1:10000), peroxidase conjugated protein A (Sigma; 1:10000).
Densitometric analysis of immunoblots was done by the ImageJ
program.
Immunofluorescence
Cells grown on glass chamber slides were washed in PBS, fixed
for 10 min in 4% paraformaldehyde, treated for 5 min with 0.2%
Triton X-100 and processed for immunofluorescence as previously
described [65]. The following antibodies were used: H3acK9 (04-
1003, Millipore; 1:200 dilution), H3diMeK9 (07-212, Millipore;
1:200), ER (MC20, Santa Cruz; 1:200), c-Myc (N-262, Santa
Cruz; 1:200), Miz-1 (H190, Santa Cruz; 1:200), FLAG (M2,
Sigma Aldrich; 1:1000), FITC conjugated rabbit anti-mouse IgG
(Chemicon; 1:1000) and Rhodamine conjugated goat anti-rabbit
IgG (Chemicon; 1:1000). DAPI (200 ng/ml) was used for staining
of nuclei. Images were acquired by a Nikon fluorescence light
microscope, through NIS-Elements 3.1 software. Fluorescence
intensity was determined using ImageJ software.
mRNA expression profiling and data analysis
Total RNA was extracted with TRIzol reagent (GIBCO-BRL)
according to the manufacturer’s protocol. RNA was checked for
quantity, purity, and integrity by gel electrophoresis and UV
spectrophotometric measurements: 10 mg of total RNA were used
as starting material for preparing cDNA. Preparation of
biotinylated target RNA – synthesis and cleanup of double-
stranded cDNA followed by synthesis, cleanup and fragmentation
Figure 9. Effect of Omomyc ectopic expression on proliferation and death of Rat1 and SH-SY5Y cells. A) Omomyc ability to hamper
growth and induce apoptosis of Rat1 fibroblasts is Myc dependent. Growth curves (top panels) and percentage of death cells (bottom
panels) of wild type (Rat1, left panels) and Myc null (Rat1 myc 2/2; right panels) fibroblasts over expressing – or not (Ctr) – Omomer or c-Myc and
Omomer (Myc+Omomer) [12]. B) Omomyc is able to reduce growth and promote apoptosis of the human neuroblastoma cell line SH-
SY5Y. Growth curve (left) and percentage of cell death (right) of SH-SY5Y human neuroblastoma infected with control or Omomer (FLAG-Omomer)
expressing lentiviruses. Cells (1.5610
5) were plated in multi-well plates in presence and absence of 4-OHT. Proliferation and death were assayed daily
by cell count and vital staining with trypan blue. Data represent three independent biological repeats.
doi:10.1371/journal.pone.0022284.g009
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provided in the Affymetrix GeneChip Expression Analysis
manual. Each biotin-labelled sample was hybridized onto a
GeneChipH Rat Genome Probe Array RG-U34A from Affymetrix
for 16 h at 45uC in a GeneChip Hybridization Oven - according
to the manufacturer’s recommendation. The expression probe
arrays were washed and stained through a GeneChip Fluidics
Station 400 according to the Affymetrix GeneChip Expression
Analysis manual. The probe arrays were scanned using an HP
Gene Array Scanner, controlled by the GeneChip software. Data
were processed with the GeneChip Microarray Analysis Suite
version 4.0 software (MAS 4, Affymetrix) with default analysis
settings; genes were sorted according to robust analysis rules. The
Rat1-control cell (time 0) sample was taken as reference for
calculating relative expression values as Fold Change (www.
affymetrix.com/support/technical/whitepapers.affx: Statistical Al-
gorithms Description Document). Fold Changes were computed
for Rat1-control cells at 909 following serum stimulation as well as
for the Rat1-Omomer cells at 0 and 90 minutes time points. Data
were filtered by setting a Fold Change threshold of +3 for the
activated genes and 23 for the repressed ones. All data are
MIAME compliant and the raw data were deposited in the GEO
database, with accession number GSE25039. Correspondence
Analysis (CA) was also performed on the same data, via routine
present in the SAS (Statistical Analysis Software) package. The
results obtained through CA were compared with those of the
selection through robust analysis via MAS 4 software. We
observed that 89% of genes identified by the manual procedure
as decreased at 90 min in the presence of Omomyc were also
detected by the CA. The same comparison on genes increased by
the induction of Omomyc at 90 min gave again a remarkable fit
between the two methods, with about 87% genes in common.
To determine overlap among genes downregulated by Omomyc
and Myc target genes, we crossed the Omomyc gene list with those
of the Myc cancer gene database and genes whose promoters were
reported to be occupied by Myc in ES cells [36,37]. 623 of the
genes listed in the Myc Cancer Gene database and 984 of those
listed as Myc bound targets in ES cells were present in the U34A
array; genes not represented in the U34A microarray were
excluded from the analysis. Omomyc-associated genes were
annotated using Panther software (http://www.pantherdb.org/).
Genes not assigned to a biological process (biological process
unclassified) were not included in the figures.
Luciferase reporter assay
293T cells, seeded in 24-well tissue culture plates, were transfected
with nucleolin or p21 reporters – respectively pNucL14 and p21Cip1-
Luc – driving expression of firefly luciferase, the Renilla luciferase
reporter – pRL-TK from Promega – and combinations of Myc
(cbSFLAG-c-Myc) and Omomyc (pCS-Omomyc) expressing plas-
mids. Cells were lysed 48 h later and luciferase activities were
measured by the Dual Luciferase reporter assay (Promega).
Quantitative Chromatin Immunoprecipitation
293T cells, transfected with pNucL14 or p21Cip1-Luc, together
with different combinations of cbSFLAG-c-Myc, cbSFLAG-
Omomyc, pCS c-Myc and pCS Omomyc DNA, were processed
as described in [3]. The FLAG M2 antibody (Sigma) was used for
immunoprecipitation. Real-time PCR was performed with 6 mLo f
DNA per reaction in iTAQ
TM SYBR Green Supermix (BioRad).
Accumulation of fluorescent products was monitored using a
GeneAmp 9700 Sequence Detector (ABI). Each PCR reaction
generated only the expected specific amplicon, as shown by the
melting-temperature profiles of final products. No PCR products
were observed in the absence of template. The indicated regions of
nucleolin promoter and luciferase coding sequence – used as control –
were amplified by qPCR. Background subtraction was calculated
from the amount of reporter construct immunoprecipitated by
anti-FLAG antibody in absence of FLAG-c-Myc and from the no-
antibody samples.
Primer sequences. Nucleolin: (forward) 59-CCCTTTCCGGG-
GTACTACAG-39, (reverse) 59-GGAAGAGAGGGCCAACCT-
TA-39; p21: (forward) 59-ACCGGCTGGCCTGCTGGAACT-39,
(reverse) 59-TCTGCCGCCGCTCTCTCA CCT-39; firefly lucif-
erase coding sequence: (forward) 59-GGAAAGACGATGACG-
GAAAA-39, (reverse) 59-CGGTACTTCGTCCACAAACA-39
Gene expression analysis by Real-Time PCR
Real Time PCR for gene expression analysis was performed on
cDNA retro-transcribed (kit from BIO-RAD) from total RNA
isolated by TRIzol reagent. PCR reactions were performed by iTaq
SYBR Green Supermix With ROX kit (BIO-RAD). Accumulation
of fluorescent products was monitored using a GeneAmp 9700
Sequence Detector (ABI). At least two independent amplifications
were performed for each probe, with triplicate samples. Cycle
threshold values were determined by automated analysis. Each
PCR reaction generated only the expected specific amplicon, as
shown by the melting-temperature profiles of final products. No
PCR products were observed in the absence of template.
Gadd45a: (forward) 59-CAGAGCAGAAGATCGAAAGGA-39,
(reverse) 59-GACTCCGAGCCTTGCTGA-39; Akt1 (forward) 59-
AACGACGTAGCCATTGTGAA-39, (reverse) 59-CCATCATT-
CTTGAGGAGGAAGT-39; Ccnd1 (forward) 59-GCACAACG-
CACTTTCTTTCC-39, (reverse) 59-TCCAGAAGGGCTTCAA-
TCTG-39; Erbb2 (forward) 59-AGCTCAGAGACCTGCTTTG-
G-39, (reverse) 59-AGGAGGACGAGTCCTTGTAGTG-39; Eif
3s9 (forward) 59-ACTGGCCGCTATGTGGTTAC-39, (reverse)
59-CAGCCAATAAGCATTGTCCA-39; Mxi1 (forward) 59-CG-
GATGATCAACGTGCAG-39, (reverse) 59-GCGTAGCCATG-
TTCACACTC-39; Pgk1 (forward) 59-CCAGATAACGAATAAC-
CAAAGGA-39, (reverse) 59-GACTTGGCTCCATTGTCCA-39
In vitro growth curves
To determine growth curves, 1.5610
4 cells were plated in
triplicate in 12-well plates. From the next day, cells were
trypsinized and counted daily with a haemocytometer for four
days. Cell death was assessed by trypan blue staining.
Supporting Information
Table S1 List of genes organized into two pages (UP Omomer
and DOWN Omomer) according to whether they are activated or
repressed by Omomyc upon 90 min of serum stimulation of Rat1
cells. Genes were selected according to the criteria described in
Results. Gene ID, gene symbol and name are shown, together with
the probe set ID of the Affymetrix U34A array. The last two
columns denote, respectively, whether genes are listed as
upregulated (UP) or downregulated (DOWN) by Myc in the
Myc target gene database and whether their promoters are listed
as Myc bound promoters in either one of two studies performed in
embryonic stem cells [36,37].
(XLS)
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